LENZ Therapeutics Inc
LENZ28.538USD
-1.422-4.75%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
813.34MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über LENZ Therapeutics Inc Unternehmen
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Unternehmensinformationen
BörsenkürzelLENZ
Name des UnternehmensLENZ Therapeutics Inc
IPO-datumJun 25, 2021
CEOMr. Evert (Eef) Schimmelpennink
Anzahl der mitarbeiter42
WertpapierartOrdinary Share
GeschäftsjahresendeJun 25
Addresse- -
Stadt- -
BörseNASDAQ Global Select Consolidated
Land- -
Postleitzahl- -
Telefon- -
Website- -
BörsenkürzelLENZ
IPO-datumJun 25, 2021
CEOMr. Evert (Eef) Schimmelpennink
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Marc Odrich
Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Shawn Olsson
Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
+42.00%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
3.19K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
James Mccollum
James Mccollum
Independent Director
Independent Director
--
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Independent Director
Independent Director
--
--
Jeff W. George
Jeff W. George
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Marc Odrich
Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Shawn Olsson
Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
+42.00%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
3.19K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
14.65%
Alpha Wave Global, LP
12.66%
Versant Ventures
12.15%
Ridgeback Capital Management, L.P.
6.84%
Point72 Asset Management, L.P.
6.60%
Other
47.09%
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
14.65%
Alpha Wave Global, LP
12.66%
Versant Ventures
12.15%
Ridgeback Capital Management, L.P.
6.84%
Point72 Asset Management, L.P.
6.60%
Other
47.09%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
41.87%
Hedge Fund
24.75%
Investment Advisor
21.00%
Investment Advisor/Hedge Fund
11.47%
Individual Investor
2.76%
Research Firm
0.79%
Bank and Trust
0.13%
Pension Fund
0.05%
Insurance Company
0.02%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
244
29.26M
103.53%
-770.18K
2025Q1
245
28.95M
104.22%
-285.84K
2024Q4
225
27.65M
100.55%
-350.42K
2024Q3
204
26.43M
96.17%
-1.73M
2024Q2
197
25.06M
103.06%
+4.18M
2024Q1
204
22.41M
93.92%
+12.70M
2023Q4
200
7.73M
92.24%
-2.14M
2023Q3
200
7.54M
90.13%
-2.49M
2023Q2
212
7.64M
91.96%
-2.29M
2023Q1
205
7.41M
89.08%
-2.37M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RA Capital Management, LP
4.18M
14.85%
--
--
May 07, 2025
Alpha Wave Global, LP
3.61M
12.83%
--
--
Apr 14, 2025
Versant Ventures
3.66M
12.99%
-884.80K
-19.48%
Jun 27, 2025
Ridgeback Capital Management, L.P.
1.95M
6.93%
--
--
Apr 14, 2025
Point72 Asset Management, L.P.
1.88M
6.69%
+1.03M
+120.91%
Apr 14, 2025
Paradigm BioCapital Advisors LP
1.42M
5.04%
-92.10K
-6.09%
Apr 14, 2025
The Vanguard Group, Inc.
1.20M
4.25%
+21.02K
+1.79%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.05M
3.73%
-14.66K
-1.38%
Mar 31, 2025
72 Investment Holdings, LLC
1.02M
3.62%
--
--
Mar 31, 2025
Sectoral Asset Management Inc.
977.25K
3.47%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Harbor Health Care ETF
0.91%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
SPDR S&P Pharmaceuticals ETF
0.83%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.59%
iShares Micro-Cap ETF
0.12%
Invesco Nasdaq Biotechnology ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Biotechnology ETF
0.07%
Avantis US Small Cap Equity ETF
0.05%
Vanguard US Momentum Factor ETF
0.05%
Mehr Anzeigen
Harbor Health Care ETF
Anteil0.91%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.89%
SPDR S&P Pharmaceuticals ETF
Anteil0.83%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil0.59%
iShares Micro-Cap ETF
Anteil0.12%
Invesco Nasdaq Biotechnology ETF
Anteil0.09%
ProShares Ultra Nasdaq Biotechnology
Anteil0.09%
iShares Biotechnology ETF
Anteil0.07%
Avantis US Small Cap Equity ETF
Anteil0.05%
Vanguard US Momentum Factor ETF
Anteil0.05%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Datum
Art
Verhältnis
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
